Spectral AI (NASDAQ:MDAI) Issues Earnings Results

by · The Cerbat Gem

Spectral AI (NASDAQ:MDAI – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.14) EPS for the quarter, hitting analysts’ consensus estimates of ($0.14), Zacks reports.

Here are the key takeaways from Spectral AI’s conference call:

  • Spectral AI began manufacturing its first 30 DeepView AI Systems for BARDA-supported U.S. burn-center deployments, with initial commercial sales still considered achievable in 2026. Management said procurement discussions are progressing, though deployments depend on working through each center’s purchasing process.
  • The company cut its 2026 R&D revenue outlook to approximately $13 million from $18.5 million, citing completion of the MTEC program and BARDA development work shifting to later periods. The outlook excludes device sales and any new or extended government awards.
  • Spectral AI is advancing studies and reimbursement pathways intended to support adoption: its U.K. label-expansion study has enrolled 10 patients, and the U.S. TNT study is expected to start at four to five burn centers in early December. The company has also applied for a hospital-focused Medicare add-on payment, with a decision expected by August 2027.
  • Q3 R&D revenue fell 24.7% year over year to $2.9 million, and gross margin declined to 27.2% from 42.7%, reflecting a narrower BARDA contract scope and shared development costs. Cash was $11.2 million at quarter-end, while the company reported a $3.7 million net loss.
  • The company now expects updated U.K. approval for its improved system in early 2027, later than its prior year-end expectation, delaying planned initial international sales until approval is received.

Spectral AI Price Performance

Shares of NASDAQ MDAI traded up $0.01 during mid-day trading on Tuesday, hitting $1.54. The company had a trading volume of 117,514 shares, compared to its average volume of 438,772. The stock has a market cap of $49.57 million, a price-to-earnings ratio of -4.40 and a beta of 1.25. Spectral AI has a 12 month low of $1.18 and a 12 month high of $2.97. The firm’s 50 day simple moving average is $1.57 and its two-hundred day simple moving average is $1.69.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Spectral AI from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, October 28th. Northland Securities raised shares of Spectral AI to a “strong-buy” rating in a report on Monday, July 27th. Finally, Wall Street Zen raised shares of Spectral AI from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $4.00.

Read Our Latest Report on MDAI

About Spectral AI

(Get Free Report)

Spectral AI, Inc. is a medical diagnostic technology company focused on using artificial intelligence and advanced imaging to support earlier, more objective assessment of wound healing. The company develops predictive diagnostic systems intended to help clinicians evaluate wounds and make treatment decisions. Its principal product is the DeepView System, a noninvasive imaging and artificial intelligence platform designed to assess burn wounds and predict the likelihood that injured tissue will heal without surgical intervention.

Further Reading